Certara, Inc.

Fundamentals8.0
Price Action6.0
News Sentiment7.0
AI Rating
7.0

Key Drivers

  • Strong margins
  • Robust cashflow
  • Intangibles concentration

AI
AI Summary

7.0

Certara's investment thesis has materially shifted from a services-driven cash engine to a product-and-platform growth story anchored on validated simulation IP (Simcyp, CertaraIQ, Phoenix Cloud), making near-term upside contingent on executing a SaaS transition and converting marquee regulatory wins into repeatable, multi-year software bookings. Key actionable watchpoints: sequential software bookings and NRR (>104%), the strategic outcome of the regulatory-services review (divestiture/reorg vs. reinvestment), and signs of intangible impairment or Tier‑1 deal slippage.

ProductTransition
ExecutionRisk
FDA‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • Strong margins
  • Robust cashflow
  • Intangibles concentration

CERT demonstrates strong gross profitability and cash generation with reasonable market multiples and liquidity, but persistent small net losses, high operating expenses and large intangible asset concentration leave leverage and recoverability risks elevated.

StrongCash
HighIntangibles

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below short-term SMA
  • Lower-highs pattern
  • Tightening range

Over the last month the stock has drifted down about 4.8% to $6.15, trading below its ~$6.76 short-term average and showing short-term bearish momentum with support near $6.15–$6.49 and resistance at $7.00–$7.35.

bearish
consolidation
Support Level: $6.15–$6.49
Resistance Level: $7.00–$7.35

Range narrowed between $6.15 lows and $7.35 highs over last month, signaling consolidation

Sentiment & News

7.0

Key News Insights:

  • Regulatory‑tech win
  • Strategic review
  • Mixed financials

Certara reported FY25 revenue and adj. EBITDA growth but missed Q4 EPS amid heavy investor outreach, a Regulatory Services strategic review, institutional repositioning, and a notable Simcyp regulatory win substituting for 10 human trials.

mixed
caution

Technical validation and strategic refocus bolster long‑term upside potential, but near‑term execution risks and active investor repositioning may keep the stock volatile